Boundless Bio, Inc. (BOLD): Depreciation & Amortization
$1.25M
Year ended 2025-12-31
$2.16M
Trailing 12 months to 2026-06-30
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.25M | +15.2% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $1.09M | +13.5% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $957.0K | n/a | 2025-03-27, From 2023-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | 2025-12-31 | $1.25M | +15.2% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $3.20M | -29.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $1.54M | -6.3% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $548.0K | -23.7% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $454.0K | -43.7% |
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $76.4K | -15.9% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $273.0K | -55.5% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $79.0K | -59.1% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $2.48M | +60.2% |
Compare BOLD, PGEN, XLO, AQST side by side · Screen every company in Pharmaceutical Preparations ↗